title: Proconvulsant effects of estriol, the third estrogen, in the mouse PTZ-kindling model.
abstract: The effect of estriol, the third estrogen, was evaluated for its effect on pentylenetetrazole (PTZ)-kindling model of epileptogenesis in mice followed by evaluation on kindling-induced changes in cognitive and motor functions. Kindling was induced by once every 2 days treatment with PTZ (25 mg/kg, i.p.) for 5 weeks. The seizure severity during induction of kindling and percentage incidence of animals kindled at the end of 5 weeks was recorded. Motor function was assessed using a grip strength meter while spatial memory was assessed in a cross maze. Estriol (0.005 and 0.01 mg/kg i.p.) reduced the time for induction of kindling from 5 weeks to 3 and 2 weeks for male and female mice respectively and enhanced the percentage incidence of seizures. Clomiphene (0.9 mg/kg i.p.) delayed the development of kindling and produced anticonvulsant effects. It also partially reversed the proconvulsant effects of estriol. On grip strength test and spontaneous alternation behaviour, a significant decline was observed in kindled mice which was further reduced by pre-treatment with estriol. Both clomiphene and diazepam were unable to reverse the reduced GS of PTZ-kindled mice but enhanced the percentage alternation of such animals. The study shows that estriol has powerful proconvulsant effects. Its administration in hormone replacement therapy or other indications, thus, requires careful monitoring in patients susceptible to epileptic seizures. The anticonvulsant effects of clomiphene requires further investigations.
authors.affiliation: Neurobehavioral Pharmacology Laboratory, Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi, 110062, India.
authors.forename: Aakifa
authors.initials: A
authors.lastname: Ahmad
authors.forename: Divya
authors.initials: D
authors.lastname: Vohora
mesh_terms: D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D002996:Clomiphene / Q000494:pharmacology; D003292:Convulsants / Q000494:pharmacology*; D003975:Diazepam / Q000494:pharmacology; D004195:Disease Models, Animal; D004964:Estriol / Q000494:pharmacology*; D005260:Female; D018737:Hand Strength; D007696:Kindling, Neurologic / Q000187:drug effects*; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D010433:Pentylenetetrazole / Q000494:pharmacology; D012640:Seizures / Q000139:chemically induced
chemical_list: D000927:Anticonvulsants; D003292:Convulsants; D002996:Clomiphene; D004964:Estriol; D003975:Diazepam; D010433:Pentylenetetrazole
references.citation: Brain Res. 2002 Dec 27;958(2):272-6
references.pmid: 12470862
references.citation: Epilepsia. 1986 Mar-Apr;27(2):103-8
references.pmid: 3956449
references.citation: Arch Neurol. 1988 Feb;45(2):209-10
references.pmid: 3341936
references.citation: Hum Reprod. 2000 May;15(5):1028-36
references.pmid: 10783346
references.citation: Fundam Clin Pharmacol. 2005 Oct;19(5):531-2
references.pmid: 16176330
references.citation: Arch Neurol. 1966 Nov;15(5):521-32
references.pmid: 4380963
references.citation: J Neurosci Res. 2003 Dec 1;74(5):637-43
references.pmid: 14635215
references.citation: J Neurosci. 2009 Feb 4;29(5):1457-68
references.pmid: 19193892
references.citation: Brain Res. 2001 Feb 9;891(1-2):1-6
references.pmid: 11164804
references.citation: Exp Clin Endocrinol Diabetes. 2001;109(3):168-73
references.pmid: 11409300
references.citation: Epilepsia. 2006 Sep;47(9):1423-40
references.pmid: 16981857
references.citation: J Neurosci. 2003 Dec 17;23(37):11641-52
references.pmid: 14684866
references.citation: Epilepsia. 2000;41 Suppl 6:S30-5
references.pmid: 10999516
references.citation: Arch Neurol. 1982 Dec;39(12):784
references.pmid: 7138325
references.citation: Psychosomatics. 1999 Mar-Apr;40(2):102-8
references.pmid: 10100431
references.citation: Med Hypotheses. 2003 Mar;60(3):448-52
references.pmid: 12581627
references.citation: Epilepsy Res. 2009 Jul;85(1):1-30
references.pmid: 19406620
references.citation: Epilepsia. 1985 May-Jun;26(3):252-7
references.pmid: 3159567
references.citation: Trends Neurosci. 1989 Jan;12(1):6-10
references.pmid: 2471338
references.citation: Epilepsia. 1991;32 Suppl 6:S34-7
references.pmid: 1959510
references.citation: Br J Pharmacol. 2005 Aug;145(7):880-4
references.pmid: 15951829
references.citation: Neuroscientist. 2007 Feb;13(1):77-88
references.pmid: 17229977
references.citation: Epilepsy Res. 1989 Nov-Dec;4(3):207-15
references.pmid: 2612493
references.citation: Biochim Biophys Acta. 2010 Oct;1800(10):1056-67
references.pmid: 20100545
references.citation: Pol J Pharmacol. 2000 Jan-Feb;52(1):59-62
references.pmid: 10949123
references.citation: Brain Res. 2003 Feb 28;964(2):244-9
references.pmid: 12576185
references.citation: Gen Pharmacol. 1998 Jul;31(1):47-50
references.pmid: 9595277
references.citation: Int J Biomed Sci. 2006 Dec;2(4):305-7
references.pmid: 23674997
references.citation: Epilepsia. 2000 May;41(5):510-5
references.pmid: 10802755
references.citation: Epilepsy Behav. 2004 Jun;5(3):322-8
references.pmid: 15145301
references.citation: Epilepsy Res. 1992 Dec;13(3):199-204
references.pmid: 1493782
references.citation: J Appl Physiol (1985). 2001 Dec;91(6):2785-801
references.pmid: 11717247
references.citation: Neuroscience. 2012 Apr 5;207:283-7
references.pmid: 22314318
references.citation: Steroids. 2007 May;72(5):381-405
references.pmid: 17379265